Individualized growth hormone therapy in children: Advances beyond weight-based dosing

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue SUPPL. 3, 2003, Pages 625-630

  Lee, Kuk Wha ^a   Cohen, Pinchas ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Growth hormone; Growth hormone deficiency; Insulin like growth factor binding protein 3; Insulin like growth factor 1; Monitoring; Somatotropin; Somatropin; Treatment optimization

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTHRALGIA; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER RISK; CHILD; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE MARKER; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPIPHYSIOLYSIS; GROWTH HORMONE DEFICIENCY; GROWTH STIMULATION; GYNECOMASTIA; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; INDIVIDUALIZATION; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; MENINGIOMA; OSTEOCHONDRITIS; OSTEOSARCOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

BODY WEIGHT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM;

EID: 0141960909     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kaplan SL, Underwood LE, August GP, Bell JJ, Blethen SL, Blizzard RM, Brown DR, Foley TP, Hintz RL, Hopwood NJ. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1986; i: 697-700.
2. Blethen SL, Compton P, Lippe BM, Rosenfeld RG, August GP, Johanson A. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1993; 76: 574-579.
3. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84: 1174-1183.
4. Kastrup KW, Christiansen JS, Andersen JK, Ørskov H. Increased growth rate following transfer to daily SC administration from three weekly IM injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983; 104: 148-152.
5. Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986; 75: 89-97.
6. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab 1996; 81: 1806-1809.
7. Wilson DM, Baker B, Hintz RL, Rosenfeld RG. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response. Pediatrics 1985; 76: 361-366.
8. Ranke MB, Schweizer R, Wollmann HA, Schwarze P. Dosing of growth hormone in growth hormone deficiency. Horm Res 1999; 51 (Suppl 3): 70-74.
9. Fujieda K, Hanew K, Hirano T, Igarashi Y, Nishi Y, Tachibana K, Takano K, Tanaka T, Yokoya S. Growth response to growth hormone therapy in patients with different degrees of growth hormone deficiency. Endocr J 1996; 43 (Suppl): S19-25.
10. Wit JM, Kamp GA, Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996; 39: 295-302.
11. Burns EC, Tanner JM, Preece MA, Cameron N. Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone. Eur J Pediatr 1981; 137: 155-164.
12. Hibi I, Tanaka T, Tanae A, Kagawa J, Hashimoto N, Yoshizawa A, Shizume K. The influence of gonadal function and the effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children. J Clin Endocrinol Metab 1989; 69: 221-226.
13. Wyatt DT, Mark D, Slyper A. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab 1995; 80: 3292-3297.
14. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 2000; 85: 3990-3993 [reprinted in J Pediatr Endocrinol Metab 2001; 14: 377-382].
15. Wikland KA, Kristrom B, Rosberg S, Svensson B, Nierop AF. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000; 48: 475-484.
16. Schonau E, Rauch F, Blum WF. Development of the Cologne growth prediction model. In: Prediction of Growth Response to GH Treatment: A Reference Guide. Oxfordshire: TMG Healthcare Communications Ltd, 2001; 42-53.
17. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab 2000; 85: 4212-4218.
18. Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Bramswig J, Blum WF. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 2001; 144: 13-20.
19. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996; 81: 1371-1377.
20. Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf) 2000; 53: 329-336.
21. Desmangles J-C, Buchlis JG, Shine B, Quattrin T, Almazan SP. IGF-I measurement during GH therapy: Is it useful? Pediatr Res 2001; 49: 106A.
22. Mandel SH, Moreland E, Rosenfeld RG, Gargosky SE. The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children. Endocrine 1997; 7: 351-360.
23. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG; The American Norditropin Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002; 87: 90-98.
24. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85: 3653-3660.
25. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-381.
26. Bengtsson BÅ, Johannsson G, Shalet SM, Simpson H, Sonksen PH. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000; 85: 933-942.
27. Vahl N, Juul A, Jorgensen JO, Ørskov H, Skakkebaek NE, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000; 85: 1874-1881.
28. Blethen SL, MacGillivray MH. A risk-benefit assessment of growth hormone use in children. Drug Safety 1997; 17: 303-316.
29. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study Experience. J Clin Endocrinol Metab 1996; 81: 1704-1710.
30. Carroll PV, Christ ER, Bengtsson BÅ, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-395.
31. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
32. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
33. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396.
34. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360: 273-277.
35. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robinson LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87: 3136-3141.
36. Blum WF. Insulin-like growth factors and IGF-binding proteins: their use for diagnosis of growth hormone deficiency. In: Juul A, Jorgensen JOL, eds. Growth Hormone in Adults: Physiological and Clinical Aspects. Cambridge: Cambridge University Press, 1996; 48-74.
37. Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab 1997; 82: 418-420.
38. Rikken B, Massa GG, Wit JM. Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Dutch Growth Hormone Working Group. Horm Res 1995; 43: 135-137.